Hostname: page-component-89b8bd64d-x2lbr Total loading time: 0 Render date: 2026-05-06T12:06:24.726Z Has data issue: false hasContentIssue false
  • English
  • Français

Development of health technology assessment in Central Europe

Published online by Cambridge University Press:  22 October 2009

Krisztián Kárpáti  and
János Sándor
Krisztián Kárpáti
Affiliation:
Doctoral School, Semmelweis Unversity, Üllőiút 26., H-1085, Budapest, Hungary, Assistant Professor, Health Economics and Technology Assessment, Research Centre, Corvinus University of Budapest, Fővám tér 8., H-1098, Budapest, Hungary (kkaarpaatii@yahoo.com)
János Sándor
Affiliation:
Associate Professor, Head of Division, Division of Biostatistics and Epidemiology, Department of Preventive Medicine, University of Debrecen, Kassaiút 26, H-4028 Debrecen, Hungary (janos.sandor@med.unideb.hu)
Rights & Permissions [Opens in a new window]

Extract

Once upon a time in the 1990s, if you wanted to do HTA in the Central and Eastern European countries (CEEs), you got yourself invited by Egon Jonsson and travelled to Stockholm to learn how to do HTA. There you met him and Prof. Banta and other HTA professionals from all over the world—very importantly, motivated healthcare professionals from all CEEs who were eager to learn HTA. These eminent founding fathers were always available, and were never tired if help or assistance was needed. During that time, the telephone number of HTA was known and used extensively, making it a real, living, informal HTA network. Formal HTA collaborations organized by them and funded by the European Commission, such as EUR-ASSESS, HTA EUROPE, ECHTA/ECAHI, were also crucial . . .

Information

Type
Letter to the Editor
Information
International Journal of Technology Assessment in Health Care , Volume 25 , Issue 4 , October 2009 , pp. 596 - 597
Copyright
Copyright © Cambridge University Press 2009

To the Editor:

Once upon a time in the 1990s, if you wanted to do HTA in the Central and Eastern European countries (CEEs), you got yourself invited by Egon Jonsson and travelled to Stockholm to learn how to do HTA. There you met him and Prof. Banta and other HTA professionals from all over the world—very importantly, motivated healthcare professionals from all CEEs who were eager to learn HTA. These eminent founding fathers were always available, and were never tired if help or assistance was needed. During that time, the telephone number of HTA was known and used extensively, making it a real, living, informal HTA network. Formal HTA collaborations organized by them and funded by the European Commission, such as EUR-ASSESS, HTA EUROPE, ECHTA/ECAHI, were also crucial . . .

Therefore, we read with great interest the series of excellent papers on the review of HTA history in different countries and on international level (International Society for Technology Assessment in Health Care and Health Technology Assessment International; International Journal of Technology Assessment in Health Care) (Reference Banta, Jonsson and Childs2;Reference Banta and Jonsson3;Reference Jonsson and Reiser24). This special issue of the International Journal of Technology Assessment in Health Care provides a comprehensive overview of activities in and development of HTA in the past decades.

As it is described in the journal, although development of health technology assessment was difficult in any country, former socialist countries of Eastern-Europe had to face special challenges (Reference Gulácsi, Brodszky and Péntek21). During the series of healthcare reforms and economic transitions, the Hungarian healthcare system faced two different challenges: the rising health expenditures resulted in a pressure of cutting the budget on the one hand, and the growing demands and needs of patients on the other. For many years, a simple fiscal answer tried to soften the problems focusing mainly on the expenditure side. In the past years, when HTA became more and more stronger and embedded in Hungary, health technology assessment became a promising tool in healthcare decision making.

We should emphasize the role of international organizations in the development of HTA in Hungary. As an outstanding achievement of local efforts and international support (a World Bank loan), a Health Services Management Training Center at the Semmelweis University in Budapest and a School of Public Health at the University of Debrecen was established in the middle of 1990s, both serving as an important academic institution for healthcare policy makers and hospital managers not only in Hungary but also in Central and Eastern Europe. The Health Evidence Network (HEN) of the World Health Organization (WHO) had also significant effect on the development of Hungarian HTA.

Another important milestone of HTA development in Hungary was the inclusion of HTA into the governmental decision-making process of pharmaceutical reimbursement after 1 May 2004, when Hungary joined to European Union. Although submission of an HTA report is not compulsory in Hungary in course of application for health insurance reimbursement, a health technology assessment report can provide valuable information for health insurance decision makers and can strengthen the application dossier.

The current research topics in Hungary—in line with the international literature (Reference Drummond, Iglesiasc and Cooper17;Reference Drummond, Schwartz and Jönsson18;Reference Gutiérrez-Ibarluzea, Asua and Latorre23;Reference Mühlberger, Sroczynski and Esteban26)—covers, for example, osteoporosis and arthritis (Reference Brodszky, Bálint and Géher14–Reference Brodszky, Pentek and Gulacsi16;Reference Péntek, Horváth and Boncz27;Reference Péntek, Kobelt and Czirják28), oncology and cancer screening (Reference Boncz4;Reference Boncz5;Reference Boncz, Sebestyen, Dobrossy and Otto9–Reference Boncz, Sebestyen and Pinter13;Reference Kovács, Döbrőssy, Budai, Boncz and Cornides25), healthcare financing (Reference Akkazieva, Gulacsi, Brandtmuller and Pentek1;Reference Boncz and Sebestyen6–Reference Boncz, Nagy, Sebestyen and Korosi8), and coverage policy (Reference Gulácsi19;Reference Gulácsi, Boncz and Drummond20;Reference Gulácsi, David and Dózsa22). In addition to the universities and research centers, the Hungarian National Health Insurance Fund Administration (Országos Egészségbiztosátási Pénztár, OEP) played an active role in the publication of scientific papers in the field of HTA.

Finally, we would like to highlight the important role of Professors Egon Jonsson and David Banta in the worldwide development of HTA in the past decades, with special respect to their commitment to the introduction, development, and permeation of HTA in Hungary.

References

REFERENCES

1. Akkazieva, B, Gulacsi, L, Brandtmuller, A, Pentek, M. Bridges J. Patients' preferences for healthcare system reforms in Hungary: A conjoint analysis. Appl Health Econ Health Policy. 2006;5:189–198.CrossRefGoogle ScholarPubMed
2. Banta, D, Jonsson, E, Childs, P. History of the international societies in health technology assessment: International Society for Technology Assessment in Health Care and Health Technology Assessment International. Int J Technol Assess Health Care. 2009;25 (Suppl 1):19–23.CrossRefGoogle ScholarPubMed
3. Banta, D, Jonsson, E. History of HTA: Introduction. Int J Technol Assess Health Care. 2009;25 (Suppl 1):1–6.CrossRefGoogle ScholarPubMed
4. Boncz, I. Organized nationwide breast cancer screening programme was introduced in Hungary in 2002. Swiss Med Wkly. 2006;136:328.Google ScholarPubMed
5. Boncz, I. Prevention of cervical cancer in low-resource settings. JAMA. 2006;295:1248.CrossRefGoogle ScholarPubMed
6. Boncz, I, Sebestyen, A. Economy and mortality in Eastern and Western Europe between 1945-1990: The largest medical trial of history. Int J Epidemiol. 2006;35:796–797.CrossRefGoogle Scholar
7. Boncz, I, Sebestyen, A. Financial deficits in the health services of the UK and Hungary. Lancet. 2006;368:917–918.CrossRefGoogle ScholarPubMed
8. Boncz, I, Nagy, J, Sebestyen, A, Korosi, L. Financing of health care services in Hungary. Eur J Health Econ. 2004;5:252–258.CrossRefGoogle ScholarPubMed
9. Boncz, I, Sebestyen, A, Dobrossy, L, Otto, S. The role of immunochemical testing for colorectal cancer. Lancet Oncol. 2006;7:363–364.CrossRefGoogle ScholarPubMed
10. Boncz, I, Sebestyen, A, Dobrossy, L, et al. . The organization and results of first screening round of the Hungarian nationwide organised breast cancer screening programme. Ann Oncol. 2007;18:795–799.CrossRefGoogle ScholarPubMed
11. Boncz, I, Sebestyen, A, Ember, I. Organized, nationwide cervical cancer screening programme in Hungary. Gynecol Oncol. 2007;106:272–273.CrossRefGoogle ScholarPubMed
12. Boncz, I, Sebestyen, A, Pinter, I, Battyany, I, Ember, I. The effect of an organized, nationwide breast cancer screening programme on non-organized mammography activities. J Med Screen. 2008;15:14–17.CrossRefGoogle ScholarPubMed
13. Boncz, I, Sebestyen, A, Pinter, I, et al. . Age-group specific gap between treatment cost of and mortality due to breast and colorectal cancer. J Clin Oncol. 2007;25:4501–4502.CrossRefGoogle ScholarPubMed
14. Brodszky, V, Bálint, P, Géher, P, et al. . Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment. Rheumatol Int. 2009 [Epub ahead of print].CrossRefGoogle Scholar
15. Brodszky, V, Czirják, L, Géher, P, et al. . Rituximab in patients with rheumatoid arthritis: Systematic review. Orv Hetil. 2007;148:1883–1893.CrossRefGoogle ScholarPubMed
16. Brodszky, V, Pentek, M, Gulacsi, L. Efficacy of adalimumab, etanercept, and infliximab in psoriatic arthritis based on ACR50 response after 24 weeks of treatment. Scand J Rheumatol. 2008;37:399–400.CrossRefGoogle ScholarPubMed
17. Drummond, MF, Iglesiasc, CP, Cooper, NJ. Systematic reviews and economic evaluations conducted for the National Institute for Health and Clinical Excellence in the United Kingdom: A game of two halves? Int J Technol Assess Health Care. 2008;24:146–150.CrossRefGoogle ScholarPubMed
18. Drummond, MF, Schwartz, JS, Jönsson, B, et al. . Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care. 2008;24:244–258.CrossRefGoogle ScholarPubMed
19. Gulácsi, L. The time for cost-effectiveness in the new European Union member states: The development and role of health economics and technology assessment in the mirror of the Hungarian experience. Eur J Health Econ. 2007;8:83–88.CrossRefGoogle ScholarPubMed
20. Gulácsi, L, Boncz, I, Drummond, M. Issues for countries considering introducing the “fourth hurdle”: The case of Hungary. Int J Technol Assess Health Care. 2004;20:337–341.CrossRefGoogle ScholarPubMed
21. Gulácsi, L, Brodszky, V, Péntek, M, et al. . History of health technology assessment in Hungary. Int J Technol Assess Health Care. 2009;25 (Suppl 1):120–126.CrossRefGoogle ScholarPubMed
22. Gulácsi, L, David, T, Dózsa, Cs. Pricing and reimbursement of drugs and medical devices in Hungary. Eur J Health Econ. 2002;3:271–278.Google ScholarPubMed
23. Gutiérrez-Ibarluzea, I, Asua, J, Latorre, K. Policies of screening for colorectal cancer in European countries. Int J Technol Assess Health Care. 2008;24:270–276.CrossRefGoogle ScholarPubMed
24. Jonsson, E, Reiser, SJ. The history of the International Journal of Technology Assessment in Health Care. Int J Technol Assess Health Care. 2009;25 (Suppl 1):11–18.CrossRefGoogle ScholarPubMed
25. Kovács, A, Döbrőssy, L, Budai, A, Boncz, I, Cornides, Á. Cervical screening in Hungary: Why does the “English model” work but the “Hungarian model” does not? Eur J Gynaecol Oncol. 2008;29:5–9.Google ScholarPubMed
26. Mühlberger, N, Sroczynski, G, Esteban, E, et al. . Cost-effectiveness of primarily human papillomavirus–based cervical cancer screening in settings with currently established Pap screening: A systematic review commissioned by the German Federal Ministry of Health. Int J Technol Assess Health Care. 2008;24:184–192.CrossRefGoogle ScholarPubMed
27. Péntek, M, Horváth, Cs, Boncz, I, et al. . Epidemiology of osteoporosis related fractures in Hungary by the nationwide health insurance database, 1999–2003. Osteoporos Int. 2008;19:243–249.CrossRefGoogle ScholarPubMed
28. Péntek, M, Kobelt, M, Czirják, L, et al. . Cost of rheumatoid arthritis in Hungary. J Rheumatol. 2007;34:14–37.Google ScholarPubMed